Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,050 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cell Transfer Clear all

Conditions: Sarcoma
Interventions: celecoxib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vinblastine sulfate, vincristine sulfate, conventional surgery, radiation therapy, MESNA, Filgrastim; Drug · Procedure · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 50 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 87
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 78 more

Conditions: Krabbe Disease
Interventions: FBX-101; Biological
Lead sponsor: Duke University; Other
Eligibility: Up to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Recovery Following Partial Medial Meniscectomy
Interventions: Chondrogen, Placebo; Drug
Lead sponsor: Mesoblast International Sàrl; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Indianapolis, Indiana • Bloomington, Minnesota + 1 more

Conditions: Malignant Epithelial Neoplasms
Interventions: TCR-transduced T cells, CDX-1140, Pembrolizumab; Biological · Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: In Vitro Maturation of Oocytes
Interventions: Fertilo, Medicult IVM; Biological · Device
Lead sponsor: Gameto, Inc.; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Clovis, California • Encino, California • Clearwater, Florida + 12 more

Conditions: Metastatic Pancreatic Carcinoma
Interventions: CAR2 Anti-CEA CAR-T cells; Biological
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Acne Vulgaris
Interventions: B244, Placebo; Drug
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Richardson, Texas

Conditions: Human Immunodeficiency Virus
Interventions: Intervention Arm (computer-based CARE+ Corrections tool), Educational video on opiate overdose prevention; Device · Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Gene Transfer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease, Chronic Pain
Interventions: cognitive behavioral therapy, eEducation; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Preterm Infant, Early-Onset Neonatal Sepsis, Umbilical Cord
Interventions: Placental/Umbilical Cord Blood sample; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: Up to 1 Day
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: AMV564 14-Day CIV; Drug
Lead sponsor: Amphivena Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Duarte, California • Tampa, Florida • St Louis, Missouri + 2 more

Conditions: Anal Cancer
Interventions: Self-sampling, Nylon-flocked Swab; Behavioral · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 35 Years and older
Enrollment: 572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Chicago, Illinois • Houston, Texas • Milwaukee, Wisconsin

Conditions: Metastatic Prostate Cancer
Interventions: creatine monohydrate, Placebo, Home-based, telehealth; Dietary Supplement · Other · Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Epithelial Ovarian Cancer
Interventions: CAR.B7-H3, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Interventions: Bright Light Therapy; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus Type II
Interventions: Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF); Procedure
Lead sponsor: Ageless Regenerative Institute; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Aventura, Florida

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions: Cemiplimab, Cisplatin, Docetaxel; Drug
Lead sponsor: Krzysztof Misiukiewicz; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
Interventions: Fludarabine, Total Marrow Irradiation (TMI); Drug · Radiation
Lead sponsor: Naoyuki G. Saito, M.D., Ph.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
Interventions: Darbepoetin, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 1 Hour to 24 Hours
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more

Conditions: Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor, Central Nervous System Tumor, Pediatric Cancer, Adult Cancer Patients, CNS Tumor, Childhood, CNS Tumor, Adult, Brainstem Glioma, Diffuse Midline Glioma, DMG
Interventions: BCB-276; Biological
Lead sponsor: BrainChild Bio, Inc; Industry
Eligibility: 1 Year to 26 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Lymphedema Arm
Interventions: BioBridge; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Warts, Warts Hand, Verruca
Interventions: CellFX System Device, Cryosurgery Liquid Nitrogen Sprayer; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 10
States / cities: Scottsdale, Arizona • Beverly Hills, California • Greenwood Village, Colorado + 7 more

Conditions: Sickle Cell Disease
Interventions: Sham 2D Headset Control, Passive Immersive 3D Virtual Reality, Active Immersive Interactive 3D Virtual Reality; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Fertilo In Vitro Research Study and Trial

Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)

Follow-up of Breast Cancer and Multiple Myeloma Patients Previously Enrolled in NIH Gene Therapy Studies

Computerized Cognitive Behavioral Therapy Assisted Life Management for Pain in Sickle Cell Disease

Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

Self-sampling to Optimize Anal Lesion Outcomes

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes

Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

Evaluation of Combination Therapy for Upper Extremity Lymphedema

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

Virtual Reality for SCD VOC